The effect of "Maoljobon ( whey)" on Cancer patients with chemotherapy induced "hand and foot syndrome"

The effect of "Maoljobon ( whey)" on Cancer patients with chemotherapy_ induced "hand and foot syndrome" and their quality of life

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220317054317N1

Enrollment

Registered

2022-04-04

Start date

2022-05-05

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced hand and foot syndrome.

Interventions

The brewery is the whey that is obtained as a by-product of cheese production, after the separation of milk casein, and contains lactose and a variety of proteins, minerals, vitamins, and fats. Depen

Use topically.After preparing the powder in one of the reputable laboratories, it is examined for fungi and microbes, and after making sure that no microbial and fungal counts have grown in the powde

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients over 18 years of age with hand syndrome and reason for chemotherapy, from Capecitabine, who are willing to participate in the study.

Exclusion criteria

Exclusion criteria: Patients with other skin lesions - Infection - Inflammatory bowel disease - History of severe milk allergy

Design outcomes

Primary

Measure	Time frame
The amount of pain in the lesions. Timepoint: Before the intervention, one day and one week after the intervention period. Method of measurement: visual analog scale.;Degree of waste. Timepoint: Before the intervention, one day and one week after the intervention period. Method of measurement: Common Terminology Criteria for Adverse Event.;The amount of burning and itching and numbness of the lesions. Timepoint: Before the intervention, one day and one week after the intervention period. Method of measurement: Likert Questionnaire.;Scaling rate and redness of the lesions. Timepoint: Before the intervention, one day and one week after the intervention period. Method of measurement: Dermatologist photography and opinion.	—

Measure

Time frame

The amount of pain in the lesions. Timepoint: Before the intervention, one day and one week after the intervention period. Method of measurement: visual analog scale.;Degree of waste. Timepoint: Before the intervention, one day and one week after the intervention period. Method of measurement: Common Terminology Criteria for Adverse Event.;The amount of burning and itching and numbness of the lesions. Timepoint: Before the intervention, one day and one week after the intervention period. Method of measurement: Likert Questionnaire.;Scaling rate and redness of the lesions. Timepoint: Before the intervention, one day and one week after the intervention period. Method of measurement: Dermatologist photography and opinion.

—

Secondary

Measure	Time frame
Overall quality of life. Timepoint: before the intervention and one day and one week after the intervention period. Method of measurement: (Quality of Life)questionnaire.;Quality of life of a skin patient. Timepoint: before the intervention and one day and one week after the intervention period. Method of measurement: Dermatology Life Quality Index questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Ashoori

Ghoum University of Medical Sciences

aashori@muq.ac.ir+98 25 3776 4073

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026